Background: Prophylaxis in children with hemophilia B (HB) lacks quantitative approaches that integrate both plasma exposure and tissue distribution. This study aimed to develop and validate a physiologically based pharmacokinetic (PBPK) model of factor IX (FIX) for pediatric HB. The model incorporated the binding of FIX to type IV collagen (Col4) to characterize its distribution in both plasma and extravascular tissues. Methods: A total of 20 children with severe HB were included, contributing 219 plasma samples. The base PBPK model was first established and verified using adult and plasma-derived FIX (pdFIX) data. It was subsequently extrapolated to children by integrating FIX-CTBB parameters and pediatric observations for model calibration. The validated model was used to characterize plasma pharmacokinetics, predict tissue distribution and target attainment, and simulate alternative prophylactic dosing regimens. Results: The model adequately described the plasma pharmacokinetics of FIX in children and predicted substantial extravascular distribution. Total extravascular exposure was approximately sixfold higher than plasma exposure. Marked heterogeneity in target attainment was identified across tissues. Lower target attainment was observed in the colon, pancreas, and brain, whereas delayed attainment occurred in bone and muscle. Simulations of prophylactic dosing regimens suggested that 75 IU/kg twice weekly may provide a favorable balance among sustained FIX exposure, tissue-level target attainment, and treatment burden. Conclusions: This PBPK model provides a mechanistic and quantitative framework for characterizing plasma and tissue exposure to FIX in children with HB and may support individualized optimization of FIX prophylactic dosing.
Background: Venetoclax (VEN), a selective B-cell lymphoma 2 inhibitor, has been increasingly used off-label in pediatric patients with hematologic malignancies. However, its pharmacokinetic characteristics in pediatric patients remain insufficiently characterized. Methods: An adult VEN physiologically based pharmacokinetic (PBPK) model was developed and extrapolated to children using age-dependent physiological and CYP3A4 ontogeny data. The pediatric model was calibrated and evaluated using data from 76 children with AML (203 plasma concentrations) and subsequently applied to assess food effects, age-related pharmacokinetic differences, and VEN dose-reduction scenarios during VCZ co-administration. The clinical study was registered with the Chinese Clinical Trial Registry (ChiCTR1900027146 and ChiCTR2400080307). Results: The adult and pediatric models adequately reproduced the observed VEN concentration–time profiles. At 200 mg/m2, a normal-fat meal increased predicted AUCinf and Cmax by 2.74- and 1.77-fold, respectively, versus a low-fat meal. Children aged 2–<6 years had the highest exposure; AUCinf was 1.44- and 1.91-fold higher than in the 6–<12- and 12–<18-year groups, respectively. During VCZ co-administration, reducing VEN to 50% and 25% of the full dose decreased AUC0–168h by 36.8% and 60.5% and Cmax by 42.5% and 70.5%, respectively, with minimal changes in Tmax. Conclusions: The pediatric VEN PBPK model quantitatively characterized the effects of meal conditions, developmental age, and VCZ-mediated CYP3A inhibition on VEN pharmacokinetics. These findings support administration with a normal diet, closer safety monitoring in children aged 2–<6 years receiving 200 mg/m2, and model-informed evaluation of VEN dose reduction during concomitant VCZ therapy.